TransCode Therapeutics (NASDAQ:RNAZ) is an RNA oncology company publicly traded since mid-Summer 2021 and structured around defeating cancer using RNA therapeutics. Specifically, the firm organizes around a platform of therapeutic candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The firm's lead therapeutic candidate - TTX-MC138 - is focused on treating metastatic cancer - believed to cause approximately 90% of all cancer deaths in excess worldwide of soe 9 million per year. Transcode management indicate that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Two of the Companys other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on treating tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing other therapeutic candidates and diagnostic products related to its planned therapeutics business.
